The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage
Stay up to date with the latest developments in multiple myeloma with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.
The #MultipleMyeloma Hub will be attending #Tandem25 virtually!
— Multiple Myeloma Hub (@MM_Hub) February 11, 2025
February 12–15
Honolulu, US, and online
Watch out for our updates and live social media coverage. #mmsm @ASTCT @CIBMTR pic.twitter.com/foQCJ7FXox
CONGRESS | #Tandem25 | PRESENTATION@AlGarfall, @PennMedicine, presents results from the phase II BMT CTN 1902 Target CR trial evaluating ide-cel followed by lenalidomide maintenance in patients with #MultipleMyeloma who had sub-optimal response after an auto-HCT (N = 38). At 6… pic.twitter.com/GHakkpiGD6
— Multiple Myeloma Hub (@MM_Hub) February 16, 2025
CONGRESS | #Tandem25 | PRESENTATION@AlGarfall, @PennMedicine, presents results from the phase II BMT CTN 1902 Target CR trial evaluating ide-cel followed by lenalidomide maintenance in patients with #MultipleMyeloma who had sub-optimal response after an auto-HCT (N = 38). At 6… pic.twitter.com/GHakkpiGD6
— Multiple Myeloma Hub (@MM_Hub) February 16, 2025
CONGRESS | #Tandem25 | PRESENTATION@YiLinMDPhD, @MayoClinic, shares MRD-negativity outcomes from the phase III CARTITUDE-4 trial (NCT04181827) of cilta-cel vs SoC in patients with lenalidomide-refractory #MultipleMyeloma. At a median follow-up of 33.6 months, MRD-negativity… pic.twitter.com/xIN1auiAhF
— Multiple Myeloma Hub (@MM_Hub) February 14, 2025
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content